A
Aurore Perrot
Researcher at French Institute of Health and Medical Research
Publications - 5
Citations - 70
Aurore Perrot is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Multiple myeloma & Minimal residual disease. The author has an hindex of 2, co-authored 5 publications receiving 21 citations.
Papers
More filters
Journal ArticleDOI
del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma
Jill Corre,Aurore Perrot,Denis Caillot,Karim Belhadj,Cyrille Hulin,Xavier Leleu,Mohamad Mohty,Thierry Facon,Laure Buisson,Laura Do Souto,Romain Lannes,Stephanie Dufrechou,Naïs Prade,Frédérique Orsini-Piocelle,Laurent Voillat,Arnaud Jaccard,Lionel Karlin,Margaret Macro,Sabine Brechignac,Mamoun Dib,Laurence Sanhes,Jean Fontan,Lauriane Clement-Filliatre,Jean-Pierre Marolleau,Stephane Minvielle,Philippe Moreau,Hervé Avet-Loiseau +26 more
TL;DR: This study clearly confirms the extremely poor outcome of patients displaying "double hit", but also confirms that del(17p) alone is still a very high-risk feature, confirming its value as a prognostic indicator for poor outcome.
Journal ArticleDOI
Serum albumin or body mass index: Which prognostic factor for survival in patients with acute myeloblastic leukaemia?
Lauriane Filliatre-clement,Julien Broséus,Marc Muller,Kossar Hosseini,Christine Rotonda,Luciane Schirmer,Gabrielle Roth-Guepin,Caroline Bonmati,Pierre Feugier,Marie-Christine Béné,Aurore Perrot +10 more
TL;DR: Serum albumin levels appear to be an independent prognostic factor in AML and a better parameter than BMI for evaluating the nutritional status of patients at diagnosis and the association between BMI, SA, and survival is evaluated.
Journal ArticleDOI
Multiple Myeloma: Heterogeneous in Every Way
TL;DR: In this article, the authors used single-cell analysis to predict patient prognosis and response to treatment for multiple myeloma (MM) in the bone marrow using a combination of cytogenetics and minimal residual disease.
Journal ArticleDOI
Risk and Response-Adapted Treatment in Multiple Myeloma
Titouan Cazaubiel,Olga Mulas,Lydia Montes,Anaïs Schavgoulidze,Hervé Avet-Loiseau,Jill Corre,Aurore Perrot +6 more
TL;DR: The advent of technologies detecting minimal residual disease gives the opportunity to define the quality of response to treatment with an unpreceded sensitivity and adapt treatment accordingly and even if molecular targeting is still nascent in myeloma, some molecular features are interesting to detect at relapse to determine optimal salvage treatments.
Journal ArticleDOI
Dyscrasies plasmocytaires : formes rares et atypiques
TL;DR: Il peut s’agir de maladies indolentes liees a de petits clones de plasmocytes a faible potentiel proliferatif mais qui synthetisent une immunoglobuline monoclonale potentiellement dangereuse pour certains organes.